Paris, France 22 November 2022 – Expleo is to provide its Life Sciences expertise to LFB, a pharmaceutical company specialising in manufacturing blood plasma-derived medicinal products. As part of the agreement, Expleo will contribute to the definition and management of strategy and procedures relating to ‘cleaning validation’ in a new LFB plant in Arras, France.
The LFB Group operates in a fast-paced pharmaceutical sector, developing and manufacturing medicinal products for serious and often rare diseases. The application and mastery of cutting-edge technological and digital innovations (data management, development of bio-medicinal products, etc.) are a critical step to ensuring patient needs are met and the efficient production of its medicines.
To support this, LFB has selected Expleo’s Life Science expertise to develop strategies and procedures for the ‘cleaning validation’ of equipment used in pharmaceutical manufacturing processes.
will steer and coordinate the design and implementation of reproducible procedures to help prevent possible cross-contamination and particulate contamination, in compliance with strict pharmaceutical regulations. It will also investigate any breaches or deviations from the new strategy and protocols.
The technical skills, expertise and knowledge of the pharmaceutical regulatory environment of our teams will be key to the success of this project, which is essential for the safe manufacture of blood plasma-derived medicinal products. We are proud to bring our Life Sciences expertise and delighted to extend our collaboration with LFB, which we have supported for many years,
Business Development Director Life Sciences – Biotech, at Expleo
